Literature DB >> 9932944

Acute blood glucose level and outcome from ischemic stroke. Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators.

A Bruno1, J Biller, H P Adams, W R Clarke, R F Woolson, L S Williams, M D Hansen.   

Abstract

OBJECTIVE: To study the relation between acute blood glucose level and outcome from ischemic stroke.
BACKGROUND: Hyperglycemia may augment acute ischemic brain injury and increase the risk of hemorrhagic transformation of the infarct.
METHODS: The authors analyzed the relation between admission blood glucose level (within 24 hours from ischemic stroke onset) and clinical outcome in 1,259 patients enrolled in the Trial of ORG 10172 in Acute Stroke Treatment (TOAST)-a placebo-controlled, randomized, double-blind trial to test the efficacy of a low-molecular weight heparinoid in acute ischemic stroke. Very favorable outcome was defined as a Glasgow Outcome Scale score of 1 and a modified Barthel index of 19 or 20. Neurologic improvement at 3 months was defined as a decrease by > or =4 points on the NIH Stroke Scale compared with baseline or a final score of 0. Hemorrhagic transformation of infarct was assessed within 10 days after onset of stroke with repeat cerebral CT. Stroke subtype as lacunar or nonlacunar (atherothromboembolic, cardioembolic, and other or undetermined etiology) was classified by one investigator after completion of stroke evaluation according to study protocol.
RESULTS: In all strokes combined (p = 0.03) and in nonlacunar strokes (p = 0.02), higher admission blood glucose levels were associated with worse outcome at 3 months according to multivariate logistic regression analysis adjusted for stroke severity, diabetes mellitus, and other vascular risks. In lacunar strokes, the relationship between acute blood glucose level and outcome was related to treatment. In the placebo group, higher admission blood glucose levels were associated with better outcome at 3 months. However, in the active drug group, as the glucose level increased from 50 to 150 mg/dL, the probability of a very favorable outcome decreased sharply and remained relatively unchanged as the glucose level increased further (p = 0.002, for overall effect of glucose on outcome). Acute blood glucose level was not associated with symptomatic hemorrhagic transformation of infarcts or with neurologic improvement at 3 months.
CONCLUSIONS: During acute ischemic stroke hyperglycemia may worsen the clinical outcome in nonlacunar stroke, but not in lacunar stroke, and is not associated with an increased risk of hemorrhagic transformation of the infarct.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9932944     DOI: 10.1212/wnl.52.2.280

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  94 in total

Review 1.  Medical therapy for acute ischemic stroke.

Authors:  L B Goldstein
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Cerebrovascular complications of diabetes: focus on stroke.

Authors:  Adviye Ergul; Aisha Kelly-Cobbs; Maha Abdalla; Susan C Fagan
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

3.  Impact of stroke co-morbidities on cortical collateral flow following ischaemic stroke.

Authors:  Ifechukwude J Biose; Deborah Dewar; I Mhairi Macrae; Christopher McCabe
Journal:  J Cereb Blood Flow Metab       Date:  2019-06-24       Impact factor: 6.200

4.  Influence of hyperglycemia on oxidative stress and matrix metalloproteinase-9 activation after focal cerebral ischemia/reperfusion in rats: relation to blood-brain barrier dysfunction.

Authors:  Hiroshi Kamada; Fengshan Yu; Chikako Nito; Pak H Chan
Journal:  Stroke       Date:  2007-02-01       Impact factor: 7.914

Review 5.  Bioenergetic regulation of microglia.

Authors:  Soumitra Ghosh; Erika Castillo; Elma S Frias; Raymond A Swanson
Journal:  Glia       Date:  2017-12-08       Impact factor: 7.452

Review 6.  Drug treatment of acute ischemic stroke.

Authors:  Sameer Bansal; Kiranpal S Sangha; Pooja Khatri
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

7.  Efficiency and safety of a standardized protocol for intravenous insulin therapy in ICU patients with neurovascular or head injury.

Authors:  Salmaan Kanji; Erika Jones; Rob Goddard; Hilary E Meggison; David Neilipovitz
Journal:  Neurocrit Care       Date:  2009-09-24       Impact factor: 3.210

8.  Metabolite profiling identifies a branched chain amino acid signature in acute cardioembolic stroke.

Authors:  W Taylor Kimberly; Yu Wang; Ly Pham; Karen L Furie; Robert E Gerszten
Journal:  Stroke       Date:  2013-03-21       Impact factor: 7.914

9.  Hyperglycemia in bacterial meningitis: a prospective cohort study.

Authors:  Ewout S Schut; Willeke F Westendorp; Jan de Gans; Nyika D Kruyt; Lodewijk Spanjaard; Johannes B Reitsma; Diederik van de Beek
Journal:  BMC Infect Dis       Date:  2009-05-08       Impact factor: 3.090

10.  Adaptive cerebral neovascularization in a model of type 2 diabetes: relevance to focal cerebral ischemia.

Authors:  Weiguo Li; Roshini Prakash; Aisha I Kelly-Cobbs; Safia Ogbi; Anna Kozak; Azza B El-Remessy; Derek A Schreihofer; Susan C Fagan; Adviye Ergul
Journal:  Diabetes       Date:  2009-10-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.